Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis.

Authors: Hanks, S  Adams, S  Douglas, J  Arbour, L  Atherton, DJ  Balci, S  Bode, H  Campbell, ME  Feingold, M  Keser, G  Kleijer, W  Mancini, G  McGrath, JA  Muntoni, F  Nanda, A  Teare, MD  Warman, M  Pope, FM  Superti-Furga, A  Futreal, PA  Rahman, N 
Citation: Hanks S, etal., Am J Hum Genet. 2003 Oct;73(4):791-800. Epub 2003 Aug 21.
Pubmed: (View Article at PubMed) PMID:14508707
DOI: Full-text: DOI:10.1086/378418

Juvenile hyaline fibromatosis (JHF) and infantile systemic hyalinosis (ISH) are autosomal recessive conditions characterized by multiple subcutaneous skin nodules, gingival hypertrophy, joint contractures, and hyaline deposition. We previously mapped the gene for JHF to chromosome 4q21. We now report the identification of 15 different mutations in the gene encoding capillary morphogenesis protein 2 (CMG2) in 17 families with JHF or ISH. CMG2 is a transmembrane protein that is induced during capillary morphogenesis and that binds laminin and collagen IV via a von Willebrand factor type A (vWA) domain. Of interest, CMG2 also functions as a cellular receptor for anthrax toxin. Preliminary genotype-phenotype analyses suggest that abrogation of binding by the vWA domain results in severe disease typical of ISH, whereas in-frame mutations affecting a novel, highly conserved cytoplasmic domain result in a milder phenotype. These data (1) demonstrate that JHF and ISH are allelic conditions and (2) implicate perturbation of basement-membrane matrix assembly as the cause of the characteristic perivascular hyaline deposition seen in these conditions.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 1599125
Created: 2007-01-17
Species: All species
Last Modified: 2007-01-17
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.